Levofloxacin

Generic Name: Levofloxacin

Brand Names: Levaquin, Quinsair

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₀FN_₃O_₄

CAS Number: 100986-85-4

Unique Ingredient Identifier: RIX4E89Y14

Background: Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...

Indication: In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...

Associated Conditions: Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria

Associated Therapies: -

Clinical Trials

Retrograde Intrarenal Surgery Low Risk Trial

Phase 4

Conditions: Retrograde Intrarenal Surgery
Renal Stones

Interventions: Drug: Levofloxacin
Drug: Cefmetazole (drug)

First Posted Date: 2024-12-19

Last Posted Date: 2024-12-19

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 200

Registration Number: NCT06741917

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

Phase 3

Not yet recruiting

Conditions: Drug-resistant Tuberculosis
Pulmonary Tuberculosis
Rifampin-resistant Tuberculosis

Interventions: Drug: bedaquiline
Drug: delamanid
Drug: linezolid
Drug: Levofloxacin
Drug: Clofazimine

First Posted Date: 2024-10-21

Last Posted Date: 2024-11-11

Lead Sponsor: Huashan Hospital

Target Recruit Count: 120

Registration Number: NCT06649721

Locations: 🇨🇳
Anhui Chest Hospital, Hefei, Anhui, China
🇨🇳
Beijing Tsinghua Changgun Hospital, Beijing, Beijing, China
🇨🇳
The 8th Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China

and more 36 locations

Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

Phase 3

Not yet recruiting

Conditions: Tuberculosis, Latent

Interventions: Drug: Bedaquiline
Combination Product: Isoniazid, rifapentine
Drug: Levofloxacin

First Posted Date: 2024-08-23

Last Posted Date: 2024-11-27

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 2530

Registration Number: NCT06568484

Locations: 🇵🇪
Hipolito Unanue National Hospital, Lima, Peru
🇵🇪
SES Policlinico, Lima, Peru
🇿🇦
Aurum Tembisa CRS, Tembisa, Gauteng, South Africa

and more 2 locations

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Phase 4

Recruiting

Conditions: Community Acquired Pneumonia in Children

Interventions: Drug: Ampicillin for Injection
Drug: Ceftriaxone for Injection
Drug: Amoxicillin
Drug: Ampicillin / Sulbactam Injection
Drug: Amoxicillin-clavulanate
Drug: Clindamycin
Drug: Cefprozil
Drug: Levofloxacin

First Posted Date: 2024-07-10

Last Posted Date: 2024-11-20

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 236

Registration Number: NCT06494072

Locations: 🇺🇸
Childrens Wisconsin, Milwaukee, Wisconsin, United States

Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Bismuth Subcitrate
Drug: Esomeprazole
Drug: Metronidazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Levofloxacin

First Posted Date: 2024-01-22

Last Posted Date: 2024-02-09

Lead Sponsor: National Institute of Public Health, Slovenia

Target Recruit Count: 2000

Registration Number: NCT06216639

Locations: 🇸🇮
Community Healthcare Center dr. Adolf Drolc Maribor (HCM), Maribor, Slovenia

Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy

Not Applicable

Terminated

Conditions: Traumatic Brain Injury

Interventions: Behavioral: Rehabilitation therapy
Device: Intermittent Oro-esophageal Tube Feeding
Device: Nasogastric tube feeding
Drug: Reserpine
Drug: Levofloxacin

First Posted Date: 2024-01-10

Last Posted Date: 2024-03-05

Lead Sponsor: Zeng Changhao

Target Recruit Count: 104

Registration Number: NCT06199778

Locations: 🇨🇳
Zheng da yi fu yuan hospital, Zhengzhou, Henan, China

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Phase 3

Recruiting

Conditions: Pulmonary Tuberculosis
Rifampicin-resistant Tuberculosis

Interventions: Drug: Bedaquiline
Drug: Delamanid
Drug: Contezolid
Drug: Levofloxacin
Drug: Moxifloxacin
Drug: Linezolid
Drug: Clofazimine
Drug: Cycloserine
Drug: Prothionamide
Drug: Pyrazinamide
Drug: Para-Aminosalicylic Acid
Drug: Ethambutol

First Posted Date: 2023-10-13

Last Posted Date: 2024-03-15

Lead Sponsor: Beijing Chest Hospital

Target Recruit Count: 186

Registration Number: NCT06081361

Locations: 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳
Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳
Harbin Chest Hospital, Harbin, Heilongjiang, China

and more 36 locations